Literature DB >> 2462868

Partial agonist activity of the bombesin-receptor antagonist [Leu14-psi-CH2-NH-Leu13]-bombesin in frog peptic cells.

K E Dickinson1, N Uemura, M C Sekar, H B McDaniel, W Anderson, D H Coy, B I Hirschowitz.   

Abstract

The pseudopeptide [Leu14-psi-CH2NH-Leu13]-bombesin inhibited 125I-GRP binding to membrane preparations of frog cerebrum and peptic cells, rat cerebral cortex and pancreas with IC50's of 44-250 nM (using 180 pM 125I-GRP). It was unable to stimulate amylase release from rat pancreatic acini, but antagonized competitively BB stimulated amylase release with an IC50 of 130 nM. By contrast the pseudopeptide stimulated pepsinogen secretion from frog esophageal peptic cells with an efficacy relative to bombesin of 36%, and with an EC50 of 30 nM. By virtue of its partial agonist activity it inhibited submaximal BB stimulated responses to a level equal to the pseudopeptide alone. Thus [Leu14-psi-CH2NH-Leu13]-BB differentiates certain BB receptors by exhibiting selective intrinsic efficacy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462868     DOI: 10.1016/s0006-291x(88)80994-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Bombesin, neuromedin B and neuromedin C interact with a common rat pancreatic phosphoinositide-coupled receptor, but are differentially regulated by guanine nucleotides.

Authors:  M C Sekar; N Uemura; D H Coy; B I Hirschowitz; K E Dickinson
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.

Authors:  Nieves González; Samuel A Mantey; Tapas K Pradhan; Veronica Sancho; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2009-05-20       Impact factor: 3.750

Review 3.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.